Table 1 Clinical characteristics of patients in different stages.
Characteristics | Total | Discovery set | ||||||
|---|---|---|---|---|---|---|---|---|
Total | Responders | Non-responders | P | Total | Responders | Non-responders | P | |
No. | 596 | 451(75.7%) | 145(24.3%) | Â | 226 | 160(70.8%) | 66(29.2%) | Â |
Age, year | 46.16 (23–72) | 46.01(23–69) | 46.64(23–72) | 0.40 | 46.33(23–72) | 45.88(25–69) | 47.42(23–72) | 0.18 |
FIGO stage | ||||||||
 IA2 | 2(0.3%) | 1(0.2%) | 1(0.7%) |  | 0(0.0%) | 0(0.0%) | 0(0.0%) |  |
 IB1 | 30(5.0%) | 25(5.5%) | 5(3.4%) |  | 11(4.9%) | 9(5.6%) | 2(3.0%) |  |
 IB2 | 124(20.8%) | 92(20.4%) | 32(22.1%) |  | 53(23.5%) | 32(20.0%) | 21(31.8%) |  |
 IIA | 146(24.5%) | 117(25.9%) | 29(20.0%) |  | 67(29.6%) | 47(29.4%) | 20(30.3%) |  |
 IIB | 253(42.4%) | 192(42.6%) | 61(42.1%) |  | 85(37.6%) | 64(40.0%) | 21(31.8%) |  |
 IIIA | 13(2.2%) | 9(2.0%) | 4(2.8%) |  | 5(2.2%) | 5(3.1%) | 0(0.0%) |  |
 IIIB | 28(4.7%) | 15(3.3%) | 13(9.0%) |  | 5(2.2%) | 3(1.9%) | 2(3.0%) |  |
 IA2-IIA | 302(50.7%) | 235(52.1%) | 67(46.2%) | 0.22 | 131(58.0%) | 88(55.0%) | 43(76.8%) | 0.16 |
 IIB-IIIB | 294(49.3%) | 216(47.9%) | 78(53.8%) |  | 95(42.0%) | 72(45.0%) | 23(23.2%) |  |
Histology | ||||||||
 Squamous cell carcinoma | 553(92.8%) | 417(92.5%) | 136(93.8%) | 0.59 | 210(92.9%) | 148(92.5%) | 62(93.9%) | 0.99 |
 Adenocarcinoma a | 43(7.2%) | 34(7.5%) | 9(6.2%) |  | 16(7.1%) | 12(7.5%) | 4(6.1%) |  |
Tumor size | ||||||||
 <4 | 174(29.2%) | 149(33.0%) | 25(17.2%) |  < 0.001 | 53(23.5%) | 47(29.4%) | 6(9.1%) |  < 0.001 |
 ≥4 | 422(70.8%) | 302(67.0%) | 120(82.8%) |  | 173(76.5%) | 113(70.6%) | 60(90.9%) |  |
| Â | Follow-up 1 | Follow-up 2 | ||||||
Characteristics | Total | Responders | Non-responders | P | Total | Responders | Non-responders | P |
No. | 235 | 176(74.9%) | 59(25.1%) | Â | 135 | 115(85.2%) | 20(14.8%) | Â |
Age, year | 45.74(23–72) | 45.73(23–63) | 46.31(24–72) | 0.53 | 46.6(26–61) | 46.87(26–61) | 45.05(30–55) | 0.34 |
FIGO stage | ||||||||
 IA2 | 1(0.4%) | 0(0.0%) | 1(1.7%) |  | 1(0.7%) | 1(1.7%) | 0(0.0%) |  |
 IB1 | 11(4.7%) | 10(5.7%) | 1(1.7%) |  | 8(5.9%) | 6(5.2%) | 2(10.0%) |  |
 IB2 | 50(21.3%) | 41(23.3%) | 9(15.3%) |  | 21(15.6%) | 19(16.5%) | 2(10.0%) |  |
 IIA | 52(22.1%) | 45(25.6%) | 7(11.9%) |  | 27(20.0%) | 25(21.7%) | 2(10.0%) |  |
 IIB | 94(40.0%) | 68(38.6%) | 26(44.%) |  | 74(54.8%) | 60(52.2%) | 14(70.0%) |  |
 IIIA | 7(3.0%) | 3(1.7%) | 4(6.8%) |  | 1(0.7%) | 1(0.9%) | 0(0.0%) |  |
 IIIB | 20(8.5%) | 9(5.1%) | 11(18.6%) |  | 3(2.2%) | 3(2.6%) | 0(0.0%) |  |
 IA2-IIA | 114(48.5%) | 96(54.5%) | 18(30.5%) | <0.001 | 57(42.2%) | 51(44.3%) | 6(30.0%) | 0.23 |
 IIB-IIIB | 121(51.5%) | 80(45.5%) | 41(69.5%) |  | 78(57.8%) | 64(55.7%) | 14(70.0%) |  |
Histology | ||||||||
 Squamous cell carcinoma | 208(88.5%) | 154(87.5%) | 54(91.5%) | 0.40 | 135(100.0%) | 115(100.0%) | 20(100.0%) |  |
 Adenocarcinoma a | 27(11.5%) | 22(12.5%) | 5(8.5%) |  | 0(0.0%) | 0(0.0%) | 0(0.0%) |  |
Tumor size | ||||||||
 <4 | 73(31.1%) | 61(34.7%) | 12(20.3%) | 0.04 | 48(35.6%) | 41(35.7%) | 7(35.0%) | 0.96 |
 ≥4 | 162(68.9%) | 115(65.3%) | 47(79.7%) |  | 87(64.4%) | 74(64.3%) | 13(65.0%) |  |
